Viewing Study NCT05356351


Ignite Creation Date: 2025-12-24 @ 11:42 PM
Ignite Modification Date: 2025-12-25 @ 9:33 PM
Study NCT ID: NCT05356351
Status: NOT_YET_RECRUITING
Last Update Posted: 2022-05-02
First Post: 2022-04-18
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: An Open-label, Single-arm, Multicenter Phase II Clinical Study: Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module